Affordable 3M Tegaderm Ag Mesh Dressing with Silver

3M Introduces Effective, Affordable 3M Tegaderm Ag Mesh Dressing with Silver

 

3M(TM) Tegaderm(TM) Ag Mesh Dressing with Silver (Photo: 3M)

ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 30, 2006--

- New Product Builds on the Trusted Tegaderm Line of Products -

3M today announced the launch of 3M Tegaderm Ag Mesh Dressing with Silver, a new wound care product with fast-acting, long-lasting antimicrobial barrier effectiveness against a wide range of microbes, including antibiotic-resistant bacteria such as MRSA and VRE(a).

Versatile Tegaderm Ag Mesh Dressing is a familiar, gauze-like porous material, which may be used as a primary dressing with absorbent wound fillers, or packed into tunnels or undermined areas. It's safe - noncytotoxic and nonirritating with no to minimal skin staining, and easy to use - conformable and soft, easy to cut and requires no premoistening on draining wounds.

"Tegaderm Ag Mesh Dressing with Silver is the latest innovation in the Tegaderm line of wound care products, and we're pleased to offer it as an affordable and effective addition to our family of medical products," said Patricia Oatman, 3M marketing manager.

Cost-effective Tegaderm Ag Mesh dressing provides a seven-day antimicrobial barrier for a variety of wounds, especially those that have stalled or are slow to heal, including: pressure, venous and neuropathic (diabetic) ulcers, surgical wounds, second degree burns, traumatic wounds, donor sites and abrasions. It is available in five sizes from 2 x 2 inches to 16 x 16 inches.

For more information about Tegaderm Ag Mesh dressing, visit www.3M.com/Tegaderm or call (800) 228-3957.

(a) Based on in vitro studies.

About 3M Health Care

Since inventing incise antimicrobial surgical drapes more than 30 years ago, 3M has been a worldwide leader in developing health care products and services that address infection control. 3M Health Care is dedicated to improving the practice, delivery and outcome of patient care. 3M Health Care is a leading provider of solutions for medical, dental, pharmaceutical, health information systems and personal care markets. Key brands from the 3M Medical Division include: Tegaderm, Steri-Strip, Red Dot, Littman, Micropore, Attest and Ioban.

About 3M - A Global, Diversified Technology Company

Every day, 3M people find new ways to make amazing things happen. Wherever they are, whatever they do, the company's customers know they can rely on 3M to help make their lives better. 3M's brands include Scotch, Post-it, Scotchgard, Thinsulate, Scotch-Brite, Filtrete, Command and Vikuiti. Serving customers in more than 200 countries around the world, the company's 69,000 people use their expertise, technologies and global strength to lead in major markets including consumer and office; display and graphics; electronics and telecommunications; safety, security and protection services; health care; industrial and transportation. For more information, including the latest product and technology news, visit www.3M.com.

3M, Tegaderm, Steri-Strip, Red Dot, Littman, Micropore, Attest, Ioban, Scotch, Post-it, Scotchgard, Thinsulate, Red Dot, Scotch-Brite, Filtrete, Command and Vikuiti are trademarks of 3M.

Contacts

Cohn & Wolfe
Melinda Burdette, 312-596-2909
melinda_burdette@cohnwolfe.com
Photo available

New Trial of Anticancer Drug From Genta

Genta Initiates New Trial of Anticancer Drug
Jan 29, 2006 11:22 AM

Genta Incorporated has entered the first patient into a new clinical study that will evaluate the bioactivity and safety of the company's lead anticancer drug, Genasense Injection, administered by intermittent subcutaneous injection.

The study employs a new formulation of Genasense that is five-fold more concentrated than material currently used in clinical trials. Having completed requisite animal toxicology work, the trial is proceeding pursuant to a separate investigational new drug application that was filed with the FDA.

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced cell death. By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment.

A prolonged subcutaneous infusion method using the existing intravenous formulation of the drug has been studied in patients with advanced non-Hodgkin's lymphoma. In this study the drug showed anti-tumor activity as a single agent and documented down-regulation of Bcl-2.

The new program seeks to extend these initial observations in a formal dose-ranging trial using the new, highly concentrated formulation.

"Genasense has demonstrated synergy with various treatments, such as Tarceva, interferon and radiation, all of which require multi-day schedules," commented Dr Raymond Warrell, Genta's chairman and CEO. "The new method may substantially increase patient convenience and expand the utility of Genasense, particularly in front-line and adjuvant settings."

Other resource sites:
Mesothelioma Lung Cancer
Mesothelioma Search Engine

Unfair Asbestos Legislation

 

Brayton Purcell Fighting Against Unfair Asbestos Legislation

Four clients of the Brayton Purcell law firm will travel to the capitol to fight against proposed asbestos legislation (S. 852). Three have developed cancers due to asbestos exposure; the fourth is a widow whose husband died from asbestos-related cancer.

Washington, DC (PRWEB)January 27, 2006 -- Four clients of the Brayton Purcell law firm will travel to our nation’s capitol next week to make their voices heard against S. 852. This unfair asbestos legislation would deny access to the courts for asbestos victims, who instead would be required to pursue their claims through an asbestos trust fund. Congressional analysts and other government experts predict that the trust fund would run out of money well before all asbestos victims could be compensated. Medical experts question the criteria that the bill uses to identify and classify the diseases related to asbestos.

A Father Suffering From Mesothelioma

One client, David Bakkie, was exposed to asbestos when he worked as an assembler, a lineman and a line construction supervisor. He is 50 years old and has two teenage sons, Christopher and Charles.

Last September, Mr. Bakkie was diagnosed with mesothelioma, an aggressive cancer that first attacks the membranes surrounding the lungs. The disease is caused by asbestos exposure.

A Ship Rigger’s Exposure to Asbestos

Ron Dutton is married and 51 years old. He has two daughters and a granddaughter. For many years, Mr. Dutton worked as a rigger on ships, a job that exposed him to asbestos. Like most other workers, he did not know about the danger to his health and was given no protection. Now he has asbestos–related colon cancer and asbestosis. Asbestosis is a progressive scarring of the lungs that is only caused by exposure to asbestos.

Mr. Dutton says that he is going to Washington to let the Senators know that workers who were exposed to asbestos have real illnesses and have the right to be compensated. He poses this question: “The government didn’t get in the way when asbestos manufacturers made huge profits, so why should it make it hard for people like me to be compensated when they become sick from asbestos products?”

An Asbestos Victim’s Widow

Joan Nettler Kiss became a widow last year when her husband, John, died of metastatic colon cancer. An insulator for 35 years, John Kiss was an active member of the Heat and Frost Insulators and Asbestos Workers Local 16 in San Francisco. He had worked in power plants, shipyards, and industrial and commercial sites throughout Northern California. He contracted asbestosis and colon cancer due to his exposure to asbestos at these jobs

After he retired as an insulator, Mr. Kiss began a second career as an investigator at Brayton Purcell because he wanted to help other asbestos victims. He was very proud of this job. His co–workers came to rely on his extensive knowledge of asbestos products and his ability to put clients at ease. Mr. Kiss eventually became the manager of the firm’s Investigations Department.

John Kiss had three children of his own and also helped raise two of Joan’s children. He was a proud grandfather to his eight grandchildren. He is sorely missed by his family, friends and co–workers.

A Machinist With Asbestos Lung Cancer

Mr. George Goodyard is married with four daughters. For 34 years, he worked as a machinist in naval and private shipyards. He now has asbestosis and lung cancer as the result of his on–the–job exposure to asbestos. He has had part of his lung removed, and visits his doctor every three months for a check–up and X–rays. He receives a CAT scan every six months, and hopes that his condition does not deteriorate further.

“They knew about asbestos in 1970, but didn’t tell us anything about it,” Mr. Goodyard said. “We didn't know about the risks we were taking.” He also points out that even today, the insulation used in ships may be 30 to 40 years old and contain asbestos. The asbestos can be easily disturbed and become airborne, allowing workers to breathe in asbestos fibers.

Mr. Goodyard has a court date set for later this year. However, if S. 852 becomes law, his asbestos case could be thrown out, and he would have to apply to the asbestos trust fund program instead. The delay would be a hardship for Mr. Goodyard and his family. The asbestos trust fund will not be up and running immediately, and S. 852 creates an unwieldy bureaucracy that may not be efficient or effective.

Protest Against S. 852

S. 852 is extremely bad legislation that will help asbestos–related companies, but harm people with asbestos diseases. Please call or write to your Senators and urge them to vote NO on S. 852. The bill may come before the Senate in early February, so it is important to do this right away. You can find your Senators’ names, e–mails, and telephone numbers on the U.S. Senate web site at http://www.senate.gov/general/contact_information/senators_cfm.cfm

List of Client Cases

The four clients are involved in these cases:
David Bakkie: David Bakkie vs. Asbestos Defendants, San Francisco Superior Court, No.     491129
Ron Dutton: Ronald Dutton and Terri Dutton vs. Asbestos Defendants, San Francisco Superior Court, No. 420971
Joan Nettler: Joan Nettler, et al vs. Asbestos Defendants, San Francisco Superior Court, No. 413663
George Goodyard: George Goodyard vs. Asbestos Defendants, San Francisco Superior Court, No. 434978

About Brayton Purcell
For over 20 years, Brayton Purcell has helped clients protect their legal rights in the face of devastating losses such as illness, injuries, and harm to family members. The law firm enjoys a national reputation for the high quality of its personal injury and product liability work, particularly in the area of asbestos litigation. For more information, call 415-898-1555 or visit the firm web site at http://www.braytonlaw.com.

For information about asbestos and asbestos-related diseases, see the firm’s web sites, Mesothelioma Network, http://www.mesotheliomasite.com and Asbestos Network, http://www.asbestosnetwork.com.

# # #

Press Contact: Butch LeRoy
Company Name: Brayton Purcell
Email: email protected from spam bots
Phone: 415 898-1555
Website: http://www.braytonlaw.com

---

[Editor's comments: For information on asbestos and the lung cancer called Mesothelioma that exposure to asbestos causes, please visit http://www.mesothelioma-lung-cancer.org. (hris ]

 

Safe Handling of Hazardous Drugs

 

“Safe Handling of Hazardous Drugs” Technical Paper from Baxa Corporation Now Posted on PublicRelationsNewsroom.com For Media Access Discussions from a scientific advisory board on the impact of USP 797 and the NIOSH Alert for guiding the safe handling of hazardous drugs in healthcare settings are the topics of a new technical paper posted at the Public Relations Newsroom Web site. This posting joins a related page at the Expert Information for Journalists Web site (Expert411.com) featuring James Jorgenson, RPh, MS, and Martha Polovich, MN, RN, AOCN, industry experts on the subject of safe handling. Denver, CO, December 22, 2005 --(PR.COM)-- With hazardous drug handling brought to the forefront of public scrutiny by USP 797 and the recent NIOSH Alert, a new technical paper has been posted at http://www.PublicRelationsNewsroom.com for media access. Baxa Corporation manufactures devices and systems for safe handling. packaging and distributing fluid medications. The new safe handling technical paper is found at: http://publicrelationsnewsroom.com/_wsn/page13.html The “safe handling of hazardous drugs” expert information page is found at http://www.expert411.com/_wsn/page9.html. The Journal of Community Oncology article featuring Marty Polovich and detailing hazardous drug handling risks is found at: http://www.communityoncology.net/journal/articles/0203277.pdf The NIOSH Alert, "Preventing Occupational Exposures to Antineoplastic and other Hazardous Drugs in Healthcare Settings," reflects years of work by physician, nurse, pharmacist and scientific experts in collaboration with members of the broad-based NIOSH Hazardous Drug Safe Handling working group. Among the findings in the Alert are warnings that previous workplace precautions for containing hazardous drugs have been inadequate. Examples include: * "Sessink and Bos noted that 11 of 12 studies detected cyclophosphamide in the urine of healthcare workers tested, indicating continued exposure despite safety precautions." (page 17) * "Considering all the data, the weight of the evidence in occupationally exposed cohorts demonstrates an association between exposures to hazardous drugs and increases in various measures of genotoxicity..." (page 19) * "Recent evidence summarized in this Alert documents that worker exposure to hazardous drugs is a persistent problem. Although most air sampling studies have not demonstrated significant airborne concentrations of these drugs, the methodology employed in the past has come into question...and may not be a good indicator of environmental contamination of the workplace. All studies that examined surface wipe samples have determined that surface contamination of the workplace is common and widespread." (page 41) The Alert recommends that employers improve environmental and employee protection where hazardous drugs are handled. The specific benefits of closed systems were called out: * "An investigation conducted in the US demonstrated a reduction in both the percentage of urine samples with measurable levels of cyclophosphamide or ifosfamide present and the concentration of the drugs in the urine following use of a closed-system device for six months..." (page 18) * "Transfers from primary packaging such as vials to dosing equipment (i.e., infusion bags, bottles or pumps) should be carried out using closed systems whenever possible. Devices that contain the product within a closed system during drug transfers limit the potential for aerosol generation, as well as exposure to sharps." (page 35) A leading provider of devices and systems for the preparation, handling, packaging, and administration of liquid medications, Baxa Corporation manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Headquartered in Englewood, Colorado, Baxa has subsidiaries and sales offices in Canada, the United Kingdom and Denmark, and distribution partners worldwide. Further information is available at http://www.baxa.com. Click the following link to view a presentation by Jim Jorgenson, "Using a Closed System Device to Reduce Occupational Exposure to Hazardous Drugs." Jorgenson is Director of Pharmacy for the Huntsman Cancer Institute and Associate Dean for Professional Affairs at the University of Utah: http://www.isips.org/presentations/PhaSeal/player.html ### Contacts: Marian Robinson, Vice President, Marketing Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157 Email: marian.robinson@baxa.com Maggie Chamberlin Holben, APR Absolutely Public Relations 303.984.9801, 303.669.3558 Email: maggie@absolutelypr.com

Contact Information

Baxa Corporation Maggie Chamberlin Holben, APR 303.984.9801 or 303.669.3558 maggie@absolutelypr.com http://www.baxa.com

Complete Systemic Enzyme Blend for Total Health and Well Being

 

S-Enzymes: Complete Systemic Enzyme Blend for Total Health and Well Being

S-Enzymes, new from Encinitas, California based Pure Prescriptions, Inc., is a carefully formulated blend of systemic enzymes, which act as catalysts to every chemical reaction in the body.

Encinitas,CA (PRWEB) January 25, 2006 -- Whether recovering from surgery, sports injury or merely a harsh allergic reaction, the body can use all the help it can get to repair itself quickly and effectively. Systemic enzymes can be a key ingredient to speedy recovery and the right supplement makes all the difference in the world.

S-Enzymes, new from Encinitas, CA based Pure Prescriptions, Inc., is a carefully formulated blend of systemic enzymes, which act as catalysts to every chemical reaction in the body. It is a completely natural product and chiefly designed for:
• Post-surgical recovery
• Sports injuries/trauma
• Immune support and balance
• Cardiovascular support
• Anti-inflammatory actions

The doctors at Pure Prescriptions understand that the health of the body is completely dependent upon the quantity and activity of enzymes. Therefore their goal was to develop the best supplement on the market. The naturally occurring enzymes in S-Enzymes help to rebuild and regenerate the widely diverse tissues in the body. So what sets this supplement apart from competing brands? According to scientific studies, systemic enzymes such as Serrapeptase require enteric coating. Enteric coating is necessary to prevent the degradation of these enzymes by the acidic environment (pH) of the stomach. Unlike other brands, S-Enzymes is enteric coated to ensure maximum absorption.

“I developed S-Enzymes specifically for my patients suffering from painful joints, sore muscles and poor circulation,” says Dr. Chad Larson, Pure Prescriptions’ chief nutritionist. “S-Enzymes represents the most comprehensive and effective blend of systemic enzymes, including genuine Serrapeptase."

Systemic enzymes are completely derived from natural sources and are widely considered safe and effective. S-Enzymes contains ingredients that are USP standardized. The United States Pharmacopeia (USP) is the official public standards-setting authority for all prescription and over-the-counter medicines, dietary supplements, and other healthcare products manufactured and sold in the United States.

Founded in California by Dr. Devin Ryerson in 2001, Pure Prescriptions is committed to providing sound advice, practical health knowledge and premier health products.

# # #

Press Contact: Dalyn Miller
Company Name: FREELANCE PR
Email: email protected from spam bots
Phone: 617-504-6869
Website: www.pureprescriptions.com

Healthcare Billing Abuse and Nursing Home Billing Abuse Out of Control

 

Nursing Home/Healthcare Billing Abuse Out of Control

The Americas Watchdog Corporate Whistleblower Center has just released the results of a year long study focused on Medicare & Medicaid that shows widespread billing abuse involving all aspects of healthcare. According to the report, in most cases examined, nursing homes, hospitals and or individual doctors are involved, and as usual its the US tax payer picking up the tab.

(PRWEB) January 22, 2006 -- The Corporate Whistle Blower Center has just reported its 2005 year end findings on the state of Medicare/Medicaid over billing/fraud in the United States, and according to the groups President Thomas Martin ,"the results are grim". The report included the top five areas where Medicare/Medicaid was over-billed or defrauded as follow:

1. Nursing Homes/Rehab Centers taking advantage of loop holes in Medicare/Medicaid billing proceedures that allow for widespread testing that should not have been done or were not needed. As an example an elderly patient on Medicare/Medicaid is admitted to a rehab center/nursing home with no speech problems and is sent to a speech therapist for a battery of unnecessary speech tests, or speech therapy at a cost of $5000-$10,000+. Unnecessary testing of Medicare/Medicaid patients costs the US Taxpayers tens of billions of dollars per year in unnecssary billing/fraud.

2. Most Nursing Homes/Rehab Centers are not providing anything close to mandatory time/hours per day with patients under their care. Nursing homes, rehab centers, and in some cases hospitals are required by Medicare/Medicaid to spend minimum hours per day, per patient. In most cases examined this is not happening in US nursing homes. This very wide spread practice puts at risk the patient and exposes the tax payer to a bill that should not have been paid. Needless or premature death/illness are a frequent result.

Another major result of the investigation was the discovery that illegal workers, who make up a very large percentage of all nursing home employees nationwide. Frequently these workers do not have a working knowledge of the English language. According to Thomas Martin President of Americas Watchdog; "its kind of hard to offer care to a nursing home patient on Medicare/Medicaid, if you cannot understand what the patient is telling you about their condition".

3. Doctors or Doctor Partnerships requiring Medicare/Medicaid patients to endure unnecssary testing or duplicative testing that fleeces the tax payer, and may put the patient at extreme risk. As an example, the investigation discovered Radiologists requiring the same patients to undergo the same types of testing, from other partners in the same practice group, or Cardilogists requiring heart patients to undergo the same heart tests from other cardiologists within the same practice group. Duplicative/Unnecessay medical testing/proccedures may account for 10% to 15% of all Medicare/Medicaid bills. Once again the tax payer gets stuck holding the bag at a cost of tens of billions of dollars each year.

4. Doctors perscribing the most expensive drugs (rather than generics) also account for up to 10% of all Medicare/Medicaid over-billings. While doctors can no longer take trips, or get lavish rewards directly from drug makers for perscribing the most expensive drugs, they can become a "consultant" for the drug company, and end up with the same type of lavish reward. According to Martin, Americas Watchdog, " its common that a drug company's "loyal" doctor" gets to become a drug company's "consultant", and then gets a first class, 7 day trip to Hawaii, where the doctor/"consultant" might give a one hour speech on the positive affects of an ED drug-to an empty room".

5. Botique hospitals, not for profits, or hospitals owned by doctors/investor groups are largely unregulated, and are not typically, on any federal, or state radar screen, with respect to the billings/compliance, related to Medicare or Medicaid patients. The net result of this; the taxpayer loses again. While large hospital systems or chains are forced to play by the "rules", with respect to physician recruitment, and or billing; not for profits, and or botique hospitals frequently do not play by any rules. According to Martin, "the only rule is how much money can we make and or where do we send the bill"?

City, County, State or Federal (aka VA) owned hospitals are also not held to any acceptable standard, with the net result being massive over-billing, fraud, or waste of precious Medicare/VA & Medicaid dollars. In the instance of government owned medical facilities, more patients, more medical staff, more administration, and more billings are all good things. Americas Watchdog Martin explains," this is because of the government employee motto; "if we don't use all of our money this year, we will not get as much money or more money next year". The net result is waste, fraud or abuse of Medicare/Medicaid that may dwarf the other four listed problem areas combined.

The Corporate Whistle Blower Center is always very interested in talking to healthcare workers/managers who might possess substantial proof related to Medicare or Medicaid over-billing or fraud. Individuals with substantial proof may be able to receive a significant reward for revealing their information. Americas Watchdog is the parent of the Corporate Whistleblower Center and would encourage individuals with information related to Medicare or Medicaid over-billing to contact us for a confidential interview.

If you are a law firm or a lawyer with a practice area that includes Qui Tams, Nursing Home abuse, Hospitals or class actions, Americas Watchdog has enormous reach in the investigation of, or in consulting on these types of cases. We also form Qui Tam partnerships with investors to expose wrong doing to federal agencies for a portion of the whistle blower reward.

###

Press Contact: Thomas Martin
Company Name: Americas Watchdog
Email: email protected from spam bots
Phone: 866-714-6466
Website: Http://Americaswatchdog.Com/

Treatment Options Enhanced for Pediatric Oncology Patients

 

FLAVORx Enhances Treatment Options for Pediatric Oncology Patients

Because of the struggles that young cancer patients face on a day to day basis during and after treatment, FLAVORx is dedicated to defining methods in which they can best accommodate their needs to make their situation that much more bearable. Working with several cancer-related medications and consumer responses, FLAVORx has discovered flavorings that improve several cancer medications' taste most effectively, and therefore improves patient quality of life.

Bethesda, MD (PRWEB) January 19, 2006 -- It is estimated that approximately 12,400 children in the United States are diagnosed with cancer each year. The most common childhood cancers are leukemia, lymphomas, brain tumors and bone cancers. The frequency of cancer diagnoses has risen since the 1970’s. In each individual case, cancer patients and their families must endure the pain, uncertainty and disruptions caused to their lives as a result of the diagnosis. Recognition of the needs of these pediatric oncology patients and the opportunity to improve the quality of their lives has led FLAVORx to dedicate a targeted investigation on how they can best serve the needs of childhood cancer patients.

The chemotherapy, doctor’s exams, constant discomfort of their condition and the countless medications these children must tolerate, is more than even the strongest adult could endure. Beyond the physical and medical changes to a child’s lifestyle, diagnosis and treatment also cause feelings of fear, anxiety, anger, guilt, sadness and depression. Therefore, any way of making these children’s lives a little easier, a little less painful and a little less traumatic is what FLAVORx strives for. Succeeding in this manner is what sets FLAVORx apart as a company dedicated to understanding the needs and situations of all children.

Medications used during cancer treatment are essential to alleviate or eradicate the signs of cancer from the body and can be classified into two groups: antineoplastic (cancer-fighting) or immuno-suppression (lessening the body’s reaction). These include drugs that can prevent infection, like antibiotics, or drugs that treat side effects such as nausea and pain. FLAVORx testing and research with children has shown that some flavors mask the existing tastes of certain medications better than others. Of the following common cancer medications, here are some of the most effective flavors:

1. Zofran (for nausea associated with chemotherapy)- Raspberry, Natural Orange, Bubblegum
2. Phenergan (for nausea associated with chemotherapy)- Grape, Sour Apple, Peaches and Cream
3. Acyclovir (to prevent viral infections)- Orange Cream, Banana, Cherry
4. Septra/Bactrim (to prevent some types of pneumonia)- Grape, Bubblegum, Watermelon
5. Vancomycin (an antibiotic)- Vanilla, Strawberry Cream, Grape/Bubblegum
6. Roxanol (to relieve pain)- Grape, Raspberry, Orange Cream

Because FLAVORx flavors are inert, non-allergenic, sugar-free, alcohol-free, very concentrated, as well as gluten and casein-free, they do not affect the efficacy of the medication and also comply with any specific dietary restraints (to reduce the risk of infection from food) that many oncology patients must follow.

Many years ago, a father came to FLAVORx with a problem. His young son had an inoperable brain tumor and was on a very strict regimen of medications. In anticipation of the medications’ taste, the young boy would become nauseated hours before he had to take them everyday, and simply could not keep them down. With no foreseeable solution, his parents were told if he couldn't ingest the medications necessary for his survival, they would have no choice but to return him to the hospital and administer the medications intravenously. Needlessly readmitting their son to the hospital would add unnecessary strain and suffering to an already unbearable situation. The family knew he would only be comfortable in a home setting, not in a cold, sterile hospital. They finally found FLAVORx and Kenny asked the entire family to come in to see how he could help. Kenny asked the little boy to name his favorite flavor, and without hesitation, he responded “Reese’s Peanut Butter Cups.” Kenny created a formulation using a combination of peanut butter and chocolate flavoring to pair with each of his medications.After that the young boy was able to take all of his medicine without opposition. Sadly, he only lived for eight more months but his final months were spent at home with his family and those that loved him, surrounded by familiarity. Kenny recalls, “Knowing that we were able to bring this child a little happiness at the end of his life is a feeling that I will never forget. It was a feeling of triumph over an otherwise cold world that for the most part didn’t do all it could to help a little boy, and value the importance of his life. I will always remember him and feel we succeeded by helping him and his family. After this, I vowed I would never let another child’s health and happiness fall by the wayside if I could help it.”

It is extremely important that children with compromised immunity, as in the case of cancer, take all medications prescribed by their physicians as they are precisely directed. FLAVORx has improved treatment quality in administering medicines by alleviating the unnecessary strain, trauma and more importantly, ramifications of medicinal non-compliance by improving the taste of unpalatable medications. FLAVORx President and CEO, Kenny Kramm, has brought increased pediatric oncology awareness to his company, as well as a heightened dedication to patient needs. FLAVORx offers 42 scientifically developed and safety-tested flavors to cover both over-the-counter and prescription medications and is available at most pharmacies nationwide.

For more information, please contact Teresa Chen at 800.884.5771, extension 234.

# # #

Press Contact: Teresa Chen
Company Name: FLAVORX, INC.
Email: email protected from spam bots
Phone: 240.223.0953
Website: www.flavorx.com

Carmel Pharma to Market and Distribute Clinically-Proven Closed System Transfer Device

 

Carmel Pharma, Inc. to Market and Distribute PhaSeal®, the Only Clinically-Proven Closed System Transfer Device Available Today

At the beginning of 2006, Carmel Pharma, Inc. applies its passion and undivided resources to the distribution and education of their own product, PhaSeal®--the only "clinically-proven" closed system transfer device available today. PhaSeal's unique design "contains the drug" which helps prevent occupational exposure to hazardous drugs in health care settings--a call to action required by The National Institute for Occupational Safety.

Columbus, OH (PRWEB) January 18, 2006 -- Carmel Pharma began to market and distribute PhaSeal® from its own company, Carmel Pharma Inc, based in Columbus Ohio as of January 2006.

PhaSeal is the only "clinically proven" closed system transfer device on the market today. It's unique design is meant to prevent environmental contamination and help protect healthcare employees through the preparation, administration and waste handling of hazardous drugs.

The National Institute for Occupational Safety (NIOSH) states that "working with or near hazardous drugs in health care settings may cause skin rashes, infertility, miscarriage, birth defects, and possibly leukemia or other cancers," quotes David Schneider, President of Carmel Pharma Inc. "The PhaSeal System contains the hazardous drug which prevents enviromental contamination, therefore providing healthcare workers a safer working environment. As the manufacturer, our sole focus is to continue to educate and be a valuable resource on this important safety issue."

PhaSeal's double membrane provides dry connections between system components and it's expansion chamber ensures aerosols and vapors are contained and neither over pressure or under-pressure occurs duing drug preparation.

PhaSeal was launched in the US in December of 2000 and today, more than 400 leading cancer facilities, such as MD Anderson, University of San Francisco, Standford and Texas Childrens Hospital have contributed to PhaSeal's outstanding growth. Carmel Pharma has recently been placed on the Deloitte´s Fast 500 EMEA List.

If you have questions or want more information on ordering PhaSeal, please contact Carmel Pharma, Inc. at
866-487-9250 or 614-841-0504.

Contacts:
Christine Crooks, Marketing Director Carmel Pharma, Inc.
Direct: 866-487-9250 ext. 202

Agneta Ekblad, VP Oncology Solutions Carmel Pharma Inc. Direct: 858-220-3583

David Schneider, President Carmel Pharma Inc.
Direct: 866-487-9250 ext. 201

# # #

Press Contact: Christine Crooks
Company Name: CARMEL PHARMA, INC.
Email: email protected from spam bots
Phone: 614-841-0504
Website: www.phaseal.com

Breast Cancer Wristbands Contribute To A Growing Trend

Press Release by: jennyandrews

Published on openPR 01-17-2006 09:00 am - CET

(openPR) - As the trend of breast cancer wristbands grows, a plethora of other wristband charities compete for a piece of the pie.

The original awareness wristband, known as the “Livestrong” wristband, was designed by the Lance Armstrong Foundation and was bright yellow to match the cyclist’s uniform. Lance Armstrong is most widely known for beating testicular cancer and winning the Tour de France. In an attempt to educate people on cancer and raise money for research and development, the silicone bracelets were an innovative way to get people’s attention. However, it may have worked too well. After the bracelets were featured on Oprah, they became even more popular. Soon they were being mimicked by every charity and awareness group imaginable in every possible color. It began with breast cancer awareness and grew from there. Now, you can find bracelets raising money for Tsunami victims, Katrina victims, and even on seatbelt safety awareness.

For this reason, a great deal of controversy is growing over the wristbands. Many, included Timothy Noah, Slate journalist, have contended the bracelets are little more than a fashion trend at this point and have lost their original meaning. With the multitude of colors and designs, there is almost no way to tell what charity someone is trying to support, not to mention the narcissistic idea of wanting to advertise charitable contributions in the first place. See http://www.breastcancerwristbands2.com/articles/breast-cancer-wristbands.html for more information.

Another issue comes to play when third parties sell these awareness bracelets. Often, when this happens, only a small portion of the proceeds actually goes to the intended charities. There are also several scams that sell knock-off bracelets for no charitable purpose. An effort is being made to educate people on the existence of these situations in which they may be taken for granted.

For more information go to http://www.breastcancerwristbands2.com/articles/breast-cancer-wristbands.html

Genetic Testing In The Convenience Of Your Own Home

 

Scientific Advances In The Field Of Nutrigenomics Target The Future of Disease Prevention; Customized Nutrition & Lifestyle Programs Formulated Through Genetic Testing

Genetic testing and the Nutriceutical Industry have joined forces in the pursuit of optimizing our ability to look into the future to foresee disease before it happens. The goal: to customize individual nutritional supplementation & lifestyle programs based on individual genetic “weaknesses” or "variances" that leave individuals more prone to certain diseases.

(PRWEB) January 13, 2006 -- Genetic testing and the Nutriceutical Industry have joined forces in the pursuit of optimizing our ability to look into the future to foresee disease before it happens. The goal: to customize individual nutritional supplementation & lifestyle programs based on individual genetic “weaknesses” or "variances" that leave individuals more prone to certain diseases. Many publications have highlighted the possibility of being able to identify the unique nutritional needs of an individual through genetic testing, "some time in the future". That future is now.

A Genetic/DNA Screening Analysis Kit and Personalized Analysis Report now make this healthful resource available to anyone, anytime, affordably … in the convenience of your own home. Families across America can use convenient Testing Kit products to reveal important lifestyle, nutritional, health related, and preventive analysis data within a few short weeks. This diagnostic breakthrough provides an excellent resource for those searching for answers to critical health questions.

Everyone has “unique genetic make-up”, and thus, “unique genetic weaknesses”, and unique nutritional needs. In the past, many leading medical researchers and doctors, summarized the application of nutritional supplementation as no more than the creation of expensive urine. Current research and application shows the efficacy of dietary supplementation of vitamins, minerals & and more targeted nutritional products on overall health and prevention of disease.

“Nutrigenomics” is the cutting edge science linking nutrients & other dietary bioactives (toxins, chemicals, etc) with the genetic variances. Even a slight variation in a gene or "genetic letter" can totally alter the genetic message, like changing one letter in a word can completely alter the meaning, like "deer" to "beer". Slight changes in these genetic codes can completely alter physiologic processes, and thus life-health issues. If these genetic code alterations are determined, addressing disease prevention with nutritional programs and lifestyle choices becomes “the epitome of prevention” for long-lasting, optimum health.

Knowing one’s critical genetic make-up provides the future for health related issues and prevention. Convenient, Genetic Testing provides a comprehensive preventive road map identifying variances related to Heart Health, Bone Health, Antioxidant & Detoxification Capacity, Inflammation Response, and Insulin Sensitivity. Combined with personalized Weight Management systems should the need exist, millions of Americans can enjoy a brighter future, and elevated quality of life.

Nutrigenomics is a boundless field of discovery that can be used to the human advantage. Americans can tap into this potential as an important personal resource for themselves and their families. Testing process is affordable, confidential, rapid, and results oriented. Change your life today.

For more information contact: Maureen Maples, DC, FASA www.DrMaples.ws

Dr. Maples has been helping patients fight disease and achieve their wellness & weight management goals for almost 10 years through various alternative healthcare methods.

###

Press Contact: Maureen Maples
Company Name:
Email: email protected from spam bots
Phone: 704-654-9560
Website: http://www.drmaples.ws

Proposed Asbestos Legislation Analyzed from a Historical Perspective

 

Mesothelioma.com Analyzes Proposed Asbestos Legislation from a Historical Perspective

Bill s.852, the Fairness in Asbestos Injury Resolution Act of 2005, is analyzed according to historical precedent.

(PRWEB) January 12, 2006 -- Mesothelioma.com today announced further opposition to the bill S.852 - the Fairness in Asbestos Injury Resolution Act of 2005. The bill is expected to receive intense scrutiny in the coming weeks, as it could be voted on this month or in the month of February. Mesothelioma.com was one of the first to criticize the bill on grounds that it is unfair to victims of this horrible affliction, especially United States veterans.

In recent weeks, Mesothelioma.com staffers have performed unbiased historical research and data mining using similar programs as models, uncovering some startling findings. Around the same time the United States Government Accountability Office ("GAO") reviewed four federal compensation programs designed to compensate individuals injured due to exposure to harmful substances- black lung, vaccine injury, radiation exposure, energy employees occupational illness- and determined the following:

•    The compensation programs have seen an expanded federal role and higher costs over time;
•    All four programs have been expanded to provide additional categories of claimants, cover more medical conditions, or provide additional benefits;
•    Some programs have been extended longer than planned;
•    There have been far more claims than estimated for each program;
•    There have been significant delays in completing claims for victims; and
•    It took at least 2 years for all four programs to become fully operational.

Both the release in numbers from Mesothelioma.com and the GAO put the potential costs needed to cover the trust fund at over $550 Billion. For the full results of our findings and for a review of the GAO report you can visit http://www.mesothelioma.com.

# # #

Press Contact: Steve Rinaldi
Company Name: IIMSNET.COM
Email: email protected from spam bots
Phone: 8004113359
Website: http://www.mesothelioma.com

FLAVORx Develops Products For Celiac Disease Patients

 

A Company That Cares - FLAVORx Develops Products to Accommodate Needs of Celiac Disease Patients

In response to growing demand from consumers for a gluten-free and casein-free line of FLAVORx Medicinal Flavorings, President Kenny Kramm has re-vamped the products to diminish the possibilities of allergy or adverse reactions due to diet limitations. Nearly all of the 42 flavors have been modified to cater to the needs of patients who cannot consume wheat, barley, rye, oats and dairy products.

Bethesda, MD (PRWEB) January 10, 2006 -- FLAVORx, Inc., the industry standard for the flavoring of prescription and OTC drugs, now offers medicinal flavorings safe for patients suffering from Celiac Disease, gluten intolerance or wheat allergies. Additionally, FLAVORx flavorings are now also casein-free and thus friendly to consumers who face troubles digesting dairy products. In a response to consumer requests for gluten and casein-free products, the company has taken it upon itself to re-vamp its formulations to make them safe and available to consumers of all needs.

Having received calls from many parents and pharmacists regarding the gluten and casein content in FLAVORx flavorings, Kenny Kramm, President and CEO of FLAVORx, began to realize that this was a limiting factor to many children. Thus began the modification process for the existing FLAVORx product line to address the dietary limitations that consumers with Celiac Disease face. According to Kramm, “Disease, allergy or intolerance shouldn’t prevent a child from being able to have their medication taste palatable. The limitations that these children (also teens, adults and the elderly) have to face on a day to day basis are already more than most could endure, adding bad-tasting medicine to that list is adding insult to injury.” With gluten and casein-free flavors, patients can rest-assured that they will still receive the maximum benefit from their medications, without having to worry that the addition of a flavoring could cause further complication because of a specific allergy or disease.

Working with all 42 flavors, Kramm had the formulations tested for safety and efficacy, to ensure they would still be appetizing and successful to use in medications. By making these modifications, 41 of the 42 flavors are now completely safe for consumers with a chronic reaction to gluten and/or dairy products, and also better for those consumers who may be unaware of allergic conditions. This vastly reduces any incidence of complication with allergy or adverse reaction when taking a FLAVORx medication. The one flavor that is still being modified is Strawberry Cream, which contains a very small amount of casein, a milk protein; however FLAVORx researchers are currently working to alter this component while maintaining the taste characteristics and medication covering properties.

Celiac Disease is the result of an adverse reaction to glutens that causes destruction of villi in the small intestine and results in inadequate nutrient absorption. Patients with Celiac Disease are typically unable to consume gluten products containing wheat, rye, barley and oats including common items like breads, pasta, cookies and even alcoholic beverages like beer. Celiac Disease affects 1 in 133 Americans, and there is no prescriptive cure for Celiacs, except to maintain a gluten-free diet. Doing so allows for immediate repair of villi in the small intestine, and likewise regression back to a diet containing gluten can be immediately detrimental. Therefore, even a small amount of gluten, like that in a few drops of flavoring, could cause a negative reaction. When asked why he took such great lengths to ensure that the flavorings were absolutely without gluten or casein, Kramm simply stated, “When it comes to medicine, you just can’t be too careful and everybody’s health circumstances must be taken into consideration.”    

Symptoms of Celiac Disease include both intestinal and non-intestinal disorders including abdominal pain, general swelling, hair loss and malnutrition, as well as additional complications like lactose intolerance. Similarly, allergies and intolerance to gluten and casein can lead to such reactions as GI symptoms (gas, bloating) and respiratory problems.

FLAVORx’s development of flavors that are gluten and casein-free exemplifies the company’s dedication to consumer needs, so patients can be confident that flavoring their medications will not cause adverse reactions to their medications.

For more information, please visit www.flavorx.com or contact Teresa Chen at 800.884.5771, extension 234.

###

Press Contact: Teresa Chen
Company Name: FLAVORX, INC.
Email: email protected from spam bots
Phone: 240.223.0953
Website: www.flavorx.com

Medical Risk Management Associates Grabs Award as Technology Innovator in Patient Safety

 

Medical Risk Management Associates, LLC (MRMA) Shares Top Honors as Technology Innovator in Patient Safety

Medical Risk Management Associates, LLC (MRMA) has been designated as a top award winner by the 2005 The Emerging Technologies and Healthcare Innovations Congress (TETHIC) for “Use of Technology for the Improvement of Patient Safety.” The award was given for MRMA's two software tools, Root Cause Analyst and Failure Mode Analyst, which respectively facilitate root cause analysis and failure mode & effects analysis in the healthcare environment.

Washington D.C. (PRWEB) January 11, 2006 -- The TETHIE Awards recognize healthcare industry leadership in the areas of innovation, technology, implementation, best practices, and research. In the category of technological innovation for patient safety, MRMA has been honored for its achievements in software-facilitated root cause analysis (RCA) and failure mode & effect analysis (FMEA) in the healthcare environment. MRMA's two software products guide the analysis team through the respective analytic process of RCA and FMEA, providing for direction, expert prompting, documentation, reporting and graphical presentation of the analyses. The underlying analytic logic structures have designed specifically for application to the healthcare industry.

“We are both pleased and honored to have been recognized for our contribution to patient care,” said Kenneth Hirsch, MD, PhD, medical director of MRMA. “This underscores our firm’s commitment to safety of our patients and effectiveness of the organizations that provide clinical care.”

About Medical Risk Management Associates, LLC (MRMA):
MRMA is a leading provider of patient safety software, training and consulting services, with specific focus upon the areas of Root Cause Analysis and Failure Mode & Effects Analysis. Its software and underlying analytic methodologies have been created by and for healthcare professionals, for exclusive application to the healthcare environment. Its software products are strongly supported by integrated traing and consultative services.

About The Emerging Technologies & Healthcare Innovations Congress (TETHIC):
Jointly developed by Health Care Conference Administrators, LLC and The Emergent Group, LLC, TETHIC’s purpose is to address the challenges and opportunities presented by new technology and healthcare innovation, provide a strategic setting, and present specific and practical solutions currently being implemented in the field.

To learn more about Medical Risk Management Associates, LLC and its products and services, go to www.Sentinel-Event.com.

###

Press Contact: Kenneth A Hirsch, MD, PhD
Company Name: MEDICAL RISK MANAGEMENT ASSOCIATES, LLC
Email: email protected from spam bots
Phone: 808-754-3639
Website: http://www.Sentinel-Event.com

Effective Pain Relief Without Medications: "Acupuncture Without Needles"

 

Effective Pain Relief Without Medications: Stanford Engineer Introduces Impressive New “Acupuncture Without Needles”

Gary Craig (Stanford ’62) has discovered a clear link between our bodily pains and our negative emotions. Used properly, EFT (Emotional Freedom Techniques) simultaneously removes or reduces emotional and physical pains in about 80% of the cases. The basics are available free on his website.

San Francisco, CA (PRWEB) January 9, 2006 -- A growing number of physicians are “tossing the meds” for some of their pain-ridden clients. Because of the dangers of many medications, a new “Acupuncture Without Needles” procedure is being substituted, often with astonishing results.

EFT (Emotional Freedom Techniques) is a dual-purpose method introduced by Stanford Engineer Gary Craig. After thousands of clinical uses it has proven effective 80% of the time and simultaneously removes or reduces both emotional and physical pain. The process involves stimulating established acupuncture meridian points by tapping on them with the fingertips. No needles are necessary.

As Eric Robins, MD states, "Someday the medical profession will wake up and realize that unresolved emotional issues are the main cause of 85% of all illnesses. When they do, EFT will be one of their primary healing tools...as it is for me."

EFT makes clear the link between our physical pains and our negative emotions. Once anger, stress, anxiety and fear abate with EFT, the corresponding pains usually subside. Sometimes the results are astonishing. Examples: Migraine headaches vanish on the spot, never to appear again. Frozen shoulders loosen and regain normal mobility. A gout sufferer goes dancing without pain.

As EFT user Bill Edens states, “We are very excited about this EFT program. My wife got rid of her back pain and too frequent headaches she has had for years. I no longer have acid reflux and no longer have to take a prescription drug for it.”

Hundreds more cases fill the EFT website. The basics can be learned and applied by anyone and are available free in the downloadable 79 page EFT Manual. See http://www.emofree.com/downloadeftmanual.htm?ref=prw . The finer points of EFT are available on low cost DVD sets and purchasers are encouraged to make up to 100 copies to give (not sell) to others.

For additional information, or for a complete press kit, contact:

Gary Craig
Emotional Freedom Techniques
707-785-2848
http://www.emofree.com

# # #

Press Contact: Gary Craig
Company Name: EFT
Email: email protected from spam bots
Phone: 707-785-2848
Website: http://www.emofree.com

TransTech Pharma and Boehringer Ingelheim Initiate Drug Discovery Collaboration

================================================================
Drug Discovery Online Newsletter - http://www.drugdiscoveryonline.com
Friday, January 06, 2006
================================================================

-------------------------------------
TOP NEWS STORIES
-------------------------------------

1) TransTech Pharma and Boehringer Ingelheim Initiate $54 Million Drug Discovery Collaboration
2) Perlegen Forms Collaboration With Genentech in Cancer Genetics
3) Pfizer Invests $50 Million In Perlegen Sciences
4) Quintiles Book Shows Path To High-Performance  Phase IIIB-IV Research
5) Xenogen Announces Extension of Global Licensing Agreement
6) Vaccine For Chronic Myeloid Leukemia Active In Patients With Persistent Disease
7) The Personalized Medicine Market Aims to Match the Most Appropriate Drug to the Right Person
8) Cetek Raises $10 Million To Advance Drug Discovery And Development
---------------------------------------

1) TransTech Pharma and Boehringer Ingelheim Initiate $54 Million Drug Discovery Collaboration

TransTech Pharma, Inc. recently announced a worldwide research and license collaboration with Boehringer Ingelheim GmbH using TransTech's proprietary TTP Translational Technology(R)...
http://www.drugdiscoveryonline.com/

2) Perlegen Forms Collaboration With Genentech in Cancer Genetics

Perlegen Sciences, Inc. announced today that it has begun a collaboration with Genentech, Inc. to study the genetics of cancer...
http://www.drugdiscoveryonline.com/

3) Pfizer Invests $50 Million In Perlegen Sciences

Perlegen Sciences, Inc. announced recently that Pfizer Inc has made a $50 million equity investment in Perlegen, taking a twelve percent position in the private biotechnology company...
http://www.drugdiscoveryonline.com/

4) Quintiles Book Shows Path To High-Performance  Phase IIIB-IV Research

Patients, physicians, payers and politicians are calling for more information on the risks and benefits of prescription drugs. At the same time, some organizations are questioning the value of direct-to-consumer advertising...
http://www.drugdiscoveryonline.com/

5) Xenogen Announces Extension of Global Licensing Agreement

Xenogen Corporation announced recently an extension of its licensing agreement with Novartis for up to two more years...
http://www.drugdiscoveryonline.com/

6) Vaccine For Chronic Myeloid Leukemia Active In Patients With Persistent Disease

Breakthrough Therapeutics, a privately owned biotechnology company, recently announced the presentation of positive interim data for a novel vaccine known as VAX100 for patients with persistent chronic myeloid leukemia (CML) while on imatinib mesylate (Gleevec(R); Novartis)...
http://www.drugdiscoveryonline.com/

7) The Personalized Medicine Market Aims to Match the Most Appropriate Drug to the Right Person

The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype...
http://www.drugdiscoveryonline.com/

8) Cetek Raises $10 Million To Advance Drug Discovery And Development

Cetek Corporation announced it has raised $10 million to advance its proprietary drug discovery platform and its emerging pipeline of compounds to treat cancer and infectious diseases...
http://www.drugdiscoveryonline.com/


-------------------------------------
FEATURED PRODUCTS
-------------------------------------

1) Analytical SFC with fractionation
2) Chromatography
3) LyoStar IIT Research and Development Tray Dryer
4) Nano Flow Sensor
5) Vetter Development Service
---------------------------------------

1) Analytical SFC with fractionation

Thar's analytical SFC offers faster separations (4 times faster than HPLC) due to the low viscosity of the primary mobile phase (CO2). Additionally, the analytical SFC utilizes Thar's new high pressure fluid pumping module that archieves flow rates of 0.1 g/min to 10 g/min at pressures up to 400 bar...
http://www.drugdiscoveryonline.com/

2) Chromatography

Disposable Membrane Chromatography units are designed for the rapid selection of appropriate chemistry and method development. The Mustang membrane chromatography starter kit includes both strong anion and cation exchange membrane chromatography Acrodisc® units, as well as specific endotoxin removal Acrodisc units...
http://www.drugdiscoveryonline.com/

3) LyoStar II(TM) Research and Development Tray Dryer

LyoStar II(TM) Research and Development Tray Dryer for process development for scale-up, Product processing for stability studies, Formulation work...
http://www.drugdiscoveryonline.com/

4) Nano Flow Sensor

Developed by Upchurch Scientific® in cooperation with Honeywell, this noninvasive Nano Flow Sensor reports flow rate in the nanoliter through low microliter-per-minute range...
http://www.drugdiscoveryonline.com/

5) Vetter Development Service

As specialists in the handling of highly sensitive active substances, we can guarantee that your liquid or freezedried active substances will be produced quickly, efficiently and carefully...
http://www.drugdiscoveryonline.com/

-------------------------------------
FEATURED DOWNLOAD
-------------------------------------

Datasheet:  Pallsep(TM) Vibrating Membrane Filtration Technology

In the Pallsep system, controlled horizontal oscillation moves the membrane
elements through the feed fluid over 50 times per second...
http://www.drugdiscoveryonline.com/

-------------------------------------
CONSULTING SERVICES
-------------------------------------

ProSavvy brings clients with projects together with consultants who have the right expertise. We also provide consultants the ability to access project opportunities.  Visit http://www.drugdiscoveryonline.com/ and post your project today!


-------------------------------------
TRAINING RESOURCES
-------------------------------------

Thinking About Continuing Your Education?
Let us help you find the right school for you. Whether you would like to get an Associate's Degree, Bachelor's Degree or Master's Degree we can help you pinpoint which schools to choose from.
http://www.drugdiscoveryonline.com/


-------------------------------------
TRADE PUBLICATIONS
-------------------------------------

Browse from the extensive list of complimentary trade publications. Visit http://www.drugdiscoveryonline.com/ for more information.

-------------------------------------
NEWSLETTER SUBSCRIPTION
-------------------------------------

If you do not currently receive the Drug Discovery Online newsletter and wish to become a subscriber, click here:
http://www.drugdiscoveryonline.com/

-------------------------------------
ADVERTISE ONLINE
-------------------------------------

If you are interested in advertising with Drug Discovery Online, and would like more information, click here:
http://www.drugdiscoveryonline.com/

==========================================================
(c)Copyright 2005 VertMarkets LLC, 5 Walnut Grove Drive, Suite 320, Horsham, PA 19044-2245. All rights reserved.

FW: Survivors of Radon-Induced Lung Cancer Speak Out

 

Survivors of Radon-Induced Lung Cancer Speak Out

Elizabeth Hoffmann of Milwaukee, Wisconsin is a survivor of radon induced lung cancer. Although she has never smoked, her 15-year exposure to dangerous levels of radon in her home resulted in doctors having to remove the cancerous lower lobe of her left lung prior to her 38th birthday.

(PRWEB) January 4, 2006 -- Elizabeth Hoffmann of Milwaukee, Wisconsin is a survivor of radon induced lung cancer. Although, she has never smoked, her 15-year exposure to dangerous levels of radon in her home resulted in doctors having to remove the cancerous lower lobe of her left lung prior to her 38th birthday.

More than a year ago, Liz announced the creation of a new website for Cancer Survivors Against Radon www.cansar.org. Its purpose is to put a face on radon by empowering sufferers of radon-induced lung cancer (and their families) with a unified voice and to prevent LC victims from remaining clueless.

Since few oncologists provide a potential explanation for the cause, most non-smokers diagnosed with lung cancer never make the association with radon exposure. Liz would remain clueless herself, if it had not been for the determination of her family to find out why. Her cousin mentioned radon as a possibility to her father, who tested Liz’s house for radon upon her return from the hospital. The results were over twice EPA’s Recommended Radon Action Level.

The CANSAR Registry enables non-smoking lung cancer patients and their families to register with the organization and order a free radon test kit for their home. Survivors and their families can choose to join others who are committed to warning the public about the danger of indoor radon. Approximately 50% of the people diagnosed with lung cancer have never smoked or are former smokers, including a 17% occurrence in never smokers.

“While it is obviously too late to preclude our cancer, our stories may convince others to prevent deadly radon exposure by testing and fixing,” says Liz. “We can also shape public policy by convincing lawmakers and government agencies to treat the radon issue and lung cancer with the seriousness it deserves. But it’s difficult to put together an advocacy group when 85% of the victims die within five years of being diagnosed. They’re just struggling to survive”.
    
Lucky for Liz, they caught her cancer early. The National Academy of Sciences (NAS) and EPA blame radon exposure for the deaths of 21,000 Americans annually. But, their deaths, like Liz’s cancer, could have been prevented. A simple radon test at the time she bought her home in 1988 would have alerted her and her husband to fix their house before moving in.

In April of this year Dennie Edwards, a real estate agent for Realty-One in Elyria, Ohio went to the doctor with a very bad cold. After the doctor performed a chest x-ray to check for pneumonia, he was shocked to find a 4.5-centimeter mass in his left lung. Like Liz, Dennie had never smoked. But, even though he had been a real estate agent for 31 years, he had never bothered to test his house for radon.

“To protect my liability, I always informed my clients that radon testing prior to purchase was an option, but truthfully, I really didn't care if they tested or not,” says Dennie. “Now I had to wonder whether my lung cancer had been caused by radon exposure.”

While the doctor scheduled his surgery, Dennie scheduled a radon test. The result was 10 pCi/l, (two and a half times the EPA's recommended Action Level). He had lived in the home for 12 years. He immediately called a contractor to have a mitigation system installed. Two days later he had surgery.

“I thought I was surely going to die,” says Dennie. “When I woke up choking with tubes in my throat, panic set in.” They had removed his entire left lung.

“I'm getting better. I can walk up to a mile,” he continues. “ But, I can no longer dance, lift things, or exert myself. My clients now get a very personal testimonial about the importance of testing for radon.”

Dr. Lane Mathis Price, Medical Director and Oncologist at the Decatur (AL) General Oncology Center has seen her share of lung cancer victims.

“People come into my office and say Doc Price I just don’t understand it. How can this happen to me? I don’t smoke. Nobody ever smokes around me. How can I have lung cancer?"

"Convincing the public that radon is dangerous is made more difficult because the nation’s leading housing authority, (the U.S. Department of Housing and Urban Development) refuses to take action to prevent radon exposure in our homes,” says Price. “ HUD requires a termite letter to qualify for a mortgage, yet to my knowledge a termite never killed anybody. Why are they not requiring a radon test?”

“Never underestimate the importance of prevention in all aspects of your life,” warns Dr. Michael Dick, Director of Internal Medicine at Decatur Adult Medicine. “If you’re a lung cancer victim aware of all the ways it is impacting you and your family -- you’d be kicking yourself if you knew something a simple as a radon detection device would have allowed you to prevent this from occurring.”

"There also needs to be a much greater effort to find a cure," explains Liz. "Even though lung cancer kills more Americans than breast, prostate and colorectal cancers combined, very little money is spent on lung cancer research."

In 2003, approximately $1,740 was spent on research per lung cancer death, compared with:$13,649 per breast cancer death, $10,560 per prostate cancer death and $4,581 per colorectal cancer death.

# # #

Press Contact: Dallas Jones
Company Name: AMERICAN RADON POLICY COALITION
Email: email protected from spam bots
Phone: 678-895-1639
Website: www.cansar.org